A phase II trial with bevacizumab and irinotecan for patients with primary brain tumors and progression after standard therapy

Søren Møller; Kirsten Grunnet; Steinbjørn Hansen; Henrik Pagh Schultz; Mats Holmberg; Morten Mau-Sørensen; Hans S Poulsen; Ulrik Lassen

doi:10.3109/0284186X.2012.681063

A phase II trial with bevacizumab and irinotecan for patients with primary brain tumors and progression after standard therapy

Søren Møller, Kirsten Grunnet, Steinbjørn Hansen, Henrik Pagh Schultz, Mats Holmberg, Morten Mau-Sørensen, Hans S Poulsen, Ulrik Lassen

58 Citationer (Scopus)

Abstract

The combination of irinotecan and bevacizumab has shown efficacy in the treatment of recurrent glioblastoma multiforme (GBM). A prospective, phase II study of 85 patients with various recurrent brain tumors was carried out. Primary endpoints were progression free survival (PFS) and response rate.

Originalsprog	Engelsk
Tidsskrift	Acta Oncologica
Vol/bind	51
Udgave nummer	6
Sider (fra-til)	797-804
Antal sider	8
ISSN	0284-186X
DOI	https://doi.org/10.3109/0284186X.2012.681063
Status	Udgivet - 2012

Adgang til dokumentet

10.3109/0284186X.2012.681063

Andre filer og links

Link to publication in Scopus

Citationsformater

@article{a3f1144add984311af1a93506cd1d85a,

title = "A phase II trial with bevacizumab and irinotecan for patients with primary brain tumors and progression after standard therapy",

abstract = "The combination of irinotecan and bevacizumab has shown efficacy in the treatment of recurrent glioblastoma multiforme (GBM). A prospective, phase II study of 85 patients with various recurrent brain tumors was carried out. Primary endpoints were progression free survival (PFS) and response rate.",

keywords = "Adult, Aged, Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, Brain Neoplasms, Camptothecin, Disease Progression, Female, Glioblastoma, Humans, Male, Middle Aged, Neoplasm Grading, Neoplasm Recurrence, Local, Prognosis, Prospective Studies, Standard of Care, Survival Rate, Young Adult",

author = "S{\o}ren M{\o}ller and Kirsten Grunnet and Steinbj{\o}rn Hansen and Schultz, \{Henrik Pagh\} and Mats Holmberg and Morten Mau-S{\o}rensen and Poulsen, \{Hans S\} and Ulrik Lassen",

year = "2012",

doi = "10.3109/0284186X.2012.681063",

language = "English",

volume = "51",

pages = "797--804",

journal = "Acta Oncologica",

issn = "0284-186X",

publisher = "Medical Journals Sweden AB",

number = "6",

}

TY - JOUR

T1 - A phase II trial with bevacizumab and irinotecan for patients with primary brain tumors and progression after standard therapy

AU - Møller, Søren

AU - Grunnet, Kirsten

AU - Hansen, Steinbjørn

AU - Schultz, Henrik Pagh

AU - Holmberg, Mats

AU - Mau-Sørensen, Morten

AU - Poulsen, Hans S

AU - Lassen, Ulrik

PY - 2012

Y1 - 2012

N2 - The combination of irinotecan and bevacizumab has shown efficacy in the treatment of recurrent glioblastoma multiforme (GBM). A prospective, phase II study of 85 patients with various recurrent brain tumors was carried out. Primary endpoints were progression free survival (PFS) and response rate.

AB - The combination of irinotecan and bevacizumab has shown efficacy in the treatment of recurrent glioblastoma multiforme (GBM). A prospective, phase II study of 85 patients with various recurrent brain tumors was carried out. Primary endpoints were progression free survival (PFS) and response rate.

KW - Adult

KW - Aged

KW - Antibodies, Monoclonal, Humanized

KW - Antineoplastic Combined Chemotherapy Protocols

KW - Brain Neoplasms

KW - Camptothecin

KW - Disease Progression

KW - Female

KW - Glioblastoma

KW - Humans

KW - Male

KW - Middle Aged

KW - Neoplasm Grading

KW - Neoplasm Recurrence, Local

KW - Prognosis

KW - Prospective Studies

KW - Standard of Care

KW - Survival Rate

KW - Young Adult

UR - https://www.scopus.com/pages/publications/84863879018

U2 - 10.3109/0284186X.2012.681063

DO - 10.3109/0284186X.2012.681063

M3 - Journal article

C2 - 22548369

SN - 0284-186X

VL - 51

SP - 797

EP - 804

JO - Acta Oncologica

JF - Acta Oncologica

IS - 6

ER -

A phase II trial with bevacizumab and irinotecan for patients with primary brain tumors and progression after standard therapy

Abstract

Adgang til dokumentet

Andre filer og links

Fingeraftryk

Citationsformater